Le Lézard
Classified in: Health
Subjects: SVY, LEG, AVO


NEW YORK, Aug. 17, 2022 /PRNewswire/ -- Audicus, the long-time provider and premier name in affordable, fully-customizable online hearing aids, celebrates the final FDA rule issued on Tuesday. The long-awaited rule, stemming from 2017 congressional legislation, establishes a new category of over-the-counter (OTC) hearing aids and will enable consumers with hearing loss to purchase hearing aids without the need for a prescription from an audiologist.

"It's no secret the hearing industry has been in need of a shakeup for a long time,"  Patrick Freuler, CEO of Audicus.

"It's no secret the hearing industry has been in need of a shakeup for a long time," said Patrick Freuler, Founder and CEO of Audicus. "We set out on the mission of making hearing care affordable and accessible for all over a decade ago. In that time, we've been able to save customers millions of dollars on hearing care, while helping so many people live more empowered, connected, and healthier lives. Over and over again, we've seen far too many people avoid addressing their hearing health due to high costs and lack of access, and we're excited this FDA rule will allow us to continue to provide even more affordable hearing solutions to the millions of Americans in need."

Nearly 30 million Americans could benefit from the use of hearing aids, but in a February 2022 survey, Audicus found high costs were the main prohibitor of addressing hearing issues, with about 40% of respondents noting that costs were too high. These high costs lead to many years of unaddressed hearing loss, with the average hearing aid user waiting 10 years before seeking help, according to a Johns Hopkins study that tied hearing loss to the risk of developing dementia.

"We're excited to keep breaking down these barriers and to continue our record of innovation in the space," Freuler continued. "We were the first to offer an end-to-end online customizable hearing solution, and we've continued to innovate new ways to make hearing care even more affordable. We just launched a new subscription product that lets users access advanced hearing aid technology and on-demand support for only $99/month, giving our consumers more options when it comes to easy and affordable hearing solutions."

The final FDA rule will be effective in the Fall.

About Audicus

Audicus offers award-winning, affordable hearing aids online, at a fraction of the cost of traditional audiologists. Through its innovative business model, Audicus has enabled consumers to save more than $50 million since 2012, and has helped hundreds of thousands lead more connected and empowered lives. Audicus was also the first to introduce a hearing aid subscription to members, with fully customizable hearing aids starting at $99 per month.

For more information on Audicus, visit www.audicus.com.

Media Contact:

Chelsey Seabrook
[email protected]


These press releases may also interest you

at 07:15
The "5G In Healthcare Market Size, Share & Trends Analysis Report by Component (Hardwar, Services), by Application (Remote Patient Monitoring, Connected Medical Devices), by End-use, by Region, and Segment Forecasts, 2022-2030" report has been added...

at 07:10
Aura Biosciences, Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety...

at 07:10
Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Designtm platform for genetic medicine, today announced a strategic collaboration with Sanofi for the use of Scribe's CRISPR genome editing technologies to enable...

at 07:10
Equillium, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced interim results from the Type B portion of the...

at 07:10
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing...

at 07:10
Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced today that enrollment for the Phase I clinical study of BAT2022 has been completed, showing that BAT2022 is well-tolerated and there were no DLT observed...

News published on 17 august 2022 at 15:34 and distributed by: